Tandem Diabetes Care (TNDM) EPS (Diluted) Growth (3y) (2021 - 2026)
Tandem Diabetes Care (TNDM) EPS (Diluted) Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -12.16% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 19.81% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 3.09% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 50.83% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -6.12% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 33.46% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 11.48% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 1,810.75% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 18.07% |
| 10 | Tandem Diabetes Care | 1.56 Bn | 1.10 Bn | 144.78 Mn | 17.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.72% |
| Mar 31, 2026 | 46.24% |
| Dec 31, 2025 | 68.06% |
| Sep 30, 2025 | 25.68% |
| Jun 30, 2025 | -49.31% |
| Mar 31, 2025 | -104.28% |
| Dec 31, 2024 | -58.99% |
| Sep 30, 2024 | -81.65% |
| Jun 30, 2024 | -113.87% |
| Mar 31, 2024 | -100.08% |
| Dec 31, 2023 | -54.01% |
| Sep 30, 2023 | -49.04% |
| Jun 30, 2023 | -4.48% |
| Mar 31, 2023 | -96.21% |
| Dec 31, 2022 | -95.44% |
| Sep 30, 2022 | -149.59% |
| Jun 30, 2022 | -105.19% |
| Mar 31, 2022 | 17.67% |
| Dec 31, 2021 | 36.13% |
| Sep 30, 2021 | 28.95% |